Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical TrialsMark Nelson, Miklos Salgo, Keikawus Arastéh et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2005Cited by 151
Upregulated IL-32 Expression And Reduced Gut Short Chain Fatty Acid Caproic Acid in People Living With HIV With Subclinical AtherosclerosisMohamed El‐Far, Cécile Tremblay, Mohamed Sylla et al.|Frontiers in Immunology|2021Cited by 55